Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is a single centre observational study to evaluate changes in functional images (MRI, Perfusion - CT, & FDG PET) after treatment with chemoradiotherapy.

Study Design

A single centre observational study to evaluate changes in functional images (MRI, Perfusion - CT, & FDG PET) after treatment with chemoradiotherapy.

Study Population

Patients undergoing radical CRT for anal cancer in Oxford University Hospitals NHS Trust.

Primary Objective

To evaluate changes on Diffusion Weighted MRI (DW MRI) during CRT in anal cancer.

Secondary Objectives

To evaluate changes on functional imaging (Dynamic Contrast Enhanced MRI (DCE MRI), Perfusion Computed Tomography (pCT), Blood Oxygen-dependent Magnetic Resonance Imaging (BOLD MRI), Fludeoxyglucose Positron Emission Tomography (FDG PET)) during CRT in anal cancer.

To correlate findings on different functional images.

To correlate baseline functional images with outcome of CRT.

To correlate the change in functional images over CRT with outcome of CRT.

Tertiary Objectives

To evaluate the use of T1 mapping in anal cancer.

To evaluate use of dynamic data acquired during FDG PET scan.

To use PET SUV data in a radiotherapy in silico modelling exercise to determine if dose sparing of active pelvic bone marrow (PBM) is possible without compromising target coverage by radiation.

Key Dates

Trial opened: 16 October 2014

Closed recruitment: 30 November 2017

Final analysis and publication: April 2019

Trial duration: 41 Months

Our team

  • Sarah Pearson

    OCTO Trial Management Director